Effects of Common Germ-Line Genetic Variation in Cell Cycle Genes on Ovarian Cancer Survival
Open Access
- 15 February 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (4) , 1090-1095
- https://doi.org/10.1158/1078-0432.ccr-07-1195
Abstract
Purpose: Somatic alterations have been shown to correlate with ovarian cancer prognosis and survival, but less is known about the effects on survival of common inherited genetic variation. Of particular interest are genes involved in cell cycle pathways, which regulate cell division and could plausibly influence clinical characteristics of multiple tumors types. Experimental Design: We examined associations between common germ-line genetic variation in 14 genes involved in cell cycle pathway (CCND1, CCND2, CCND3, CCNE1, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CDK2, CDK4, CDK6, and RB1) and survival among women with invasive ovarian cancer participating in a multicenter case-control study from United Kingdom, Denmark, and United States. DNAs from up to 1,499 women were genotyped for 97 single-nucleotide polymorphisms that tagged the known common variants (minor allele frequency ≥0.05) in these genes. The genotypes of each polymorphism were tested for association with survival by Cox regression analysis. Results: A nominally statistically significant association between genotype and ovarian cancer survival was observed for polymorphisms in CCND2 and CCNE1. The per-allele hazard ratios (95% confidence intervals) were 1.16 (1.03-1.31; P = 0.02) for rs3217933, 1.14 (1.02-1.27; P = 0.024) for rs3217901, and 0.85 (0.73-1.00; P = 0.043) for rs3217862 in CCND2 and 1.39 (1.04-1.85; P = 0.033) for rs3218038 in CCNE1. However, these were not significant after adjusting for multiple hypothesis tests. Conclusion: It is unlikely that common variants in cell cycle pathways examined above associated with moderate effect in survival after diagnosis of ovarian cancer. Much larger studies will be needed to exclude common variants with small effects.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupBritish Journal of Cancer, 2007
- Novel Functional Single Nucleotide Polymorphisms in the Latent Transforming Growth Factor-β Binding Protein-1L PromoterThe Journal of Molecular Diagnostics, 2006
- Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancerExperimental & Molecular Medicine, 2006
- Glutathione S-transferase polymorphisms and ovarian cancer treatment and survivalGynecologic Oncology, 2006
- mdr-1Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel ChemotherapyClinical Cancer Research, 2006
- TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancerBiochemical and Biophysical Research Communications, 2005
- AIB1 Polymorphisms Predict Aggressive Ovarian Cancer PhenotypeCancer Epidemiology, Biomarkers & Prevention, 2005
- The influence of HER2 genotypes as molecular markers in ovarian cancer outcomeBiochemical and Biophysical Research Communications, 2005
- Association studies for finding cancer-susceptibility genetic variantsNature Reviews Cancer, 2004
- Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancerInternational Journal of Gynecologic Cancer, 1999